Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 115
- Registration Number
- NCT01104298
- Locations
- 🇪🇸
H. Sant Pau, Barcelona, Spain
🇪🇸ICO Badalona, Badalona, Spain
🇪🇸ICO Girona, Girona, Spain
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-12-10
- Target Recruit Count
- 121
- Registration Number
- NCT00796120
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2014-04-11
- Target Recruit Count
- 76
- Registration Number
- NCT00786838
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2014-02-25
- Target Recruit Count
- 127
- Registration Number
- NCT00580112
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2014-05-07
- Target Recruit Count
- 29
- Registration Number
- NCT00579501
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 71
- Registration Number
- NCT00569673
- Locations
- 🇺🇸
St. John's Regional Health Center, Springfield, Missouri, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 20
- Registration Number
- NCT00379145
- Locations
- 🇺🇸
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
- Conditions
- Sarcoma
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT00210665
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00147212
- Locations
- 🇺🇸
Masachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2005-06-10
- Last Posted Date
- 2014-06-27
- Target Recruit Count
- 672
- Registration Number
- NCT00113607
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.